Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?

References 

1. (Abstract 581) Chan S, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anythracycline pretreated metastatic breast cancer (MBC) patients (pts): results of a European Phase III study. In: Proc Am Soc Clin Oncol. 2005;
2. Blum JL, Jones SE, Buzdar AU, et al. A multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–493
   • MEDLINE
3. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial of gemcitabine. J Clin Oncol. 1995;13:2731–2736
   • MEDLINE
4. Abstract A663 Spielman M, Kalla S, Llambart-Cussac A, et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer. 1997;33(Suppl 8):
5. Copenhagen, Denmark (Abstract 670) Ravdin P, Erban J, Overmoyer B, et al. Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer. In: Proceedings from the 12th European Conference on Clinical Oncology. Sept 21–25. 2003;
6. Abstract 10 Jones S, Erban J, Overmoyer B, et al. In: Breast Cancer Research and Treatment, 82: Special Issue: 26th Annual San Antonio Breast Cancer Symposium. 2003;
7. Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest. 2000;18(6):503–509
   • MEDLINE
   • CrossRef
8. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicentre phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol. 1999;10(2):211–215
   • MEDLINE
   • CrossRef
9. Abstract 1956 Brandi M, Giotta F, Vici P, et al. Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): preliminary results of a multicenter phase II trial of GOIM. In: Proc Am Soc Clin Oncol. 2001;
10. Laufman LR, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol. 2001;12(9):1259–1264
    • MEDLINE
    • CrossRef
11. Lenz F, Beldermann F, Geberth M, et al. A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated HER-2 negative metastatic breast cancer. Eur J Cancer Suppl. 2003;1(5):S139
12. Kornek GV, Haider K, Kwasny W, et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res. 2003;8:1051–1056
    • MEDLINE
13. Mavroudis D, Malamos N, Polysos A, et al. Front-line chemotherapy with docetaxel and gemcitabine every two weeks in patients with metastatic breast cancer: a multi-center phase II study. Oncology. 2004;67(3–4):250–256
    • MEDLINE
    • CrossRef
14. Abstract 201 Garle PA, Calvo L, Mayordomo I, et al. Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer (MBC): Final results of a phase II study conducted within the Breast Cancer Investigaton Spanish Group (GEICAM). In: Proc Am Soc Clin Oncol. 2003;
15. (14S, July 15 Suppl) Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. In: J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22:2004;p. 15
16. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase II trial results. J Clin Oncol. 2002;12:2812–2823